{"id":"ipv-at-6-weeks-of-age","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Local injection site reactions (pain, redness, swelling)"},{"rate":"1-3","effect":"Fever"},{"rate":"1-3","effect":"Irritability or fussiness"},{"rate":"<1","effect":"Mild rash"}]},"_chembl":{"chemblId":"CHEMBL4303347","moleculeType":"Small molecule","molecularWeight":"455.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IPV contains chemically inactivated (killed) poliovirus strains that cannot cause disease but retain their antigenic properties. When administered, these inactivated viruses trigger both humoral (antibody) and cellular immune responses, leading to the production of neutralizing antibodies against all three poliovirus serotypes. This provides protection against wild-type poliovirus infection and prevents poliomyelitis.","oneSentence":"IPV (Inactivated Poliovirus Vaccine) stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by introducing inactivated viral particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:29.369Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis in infants and children"},{"name":"Routine immunization at 6 weeks of age as part of childhood vaccination schedule"}]},"trialDetails":[{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT05644184","phase":"PHASE2","title":"Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh","status":"RECRUITING","sponsor":"PATH","startDate":"2023-03-27","conditions":"Poliomyelitis","enrollment":2232},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT07010822","phase":"PHASE3","title":"A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants","status":"NOT_YET_RECRUITING","sponsor":"Fidec Corporation","startDate":"2025-12-08","conditions":"Poliomyelitis","enrollment":740},{"nctId":"NCT06577298","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-19","conditions":"Poliomyelitis","enrollment":480},{"nctId":"NCT06947499","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","status":"RECRUITING","sponsor":"LG Chem","startDate":"2025-05-30","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1186},{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT06413121","phase":"PHASE3","title":"Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-05-06","conditions":"Diptheria Immunization, Tetanus Immunization, Pertussis Immunization","enrollment":1557},{"nctId":"NCT05677256","phase":"PHASE4","title":"A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2023-11-09","conditions":"Poliomyelitis","enrollment":500},{"nctId":"NCT05654467","phase":"PHASE2","title":"Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama","status":"UNKNOWN","sponsor":"PATH","startDate":"2023-12-05","conditions":"Poliomyelitis","enrollment":1532},{"nctId":"NCT03554798","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2018-12-04","conditions":"Poliomyelitis","enrollment":1025},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT05457946","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-04-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1438},{"nctId":"NCT04063150","phase":"PHASE4","title":"Immunogenicity of Intramuscular and Intradermal IPV","status":"TERMINATED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-06","conditions":"Poliomyelitis","enrollment":958},{"nctId":"NCT02817451","phase":"PHASE3","title":"DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-14","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":53},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT03202719","phase":"PHASE4","title":"Duration of IPV Priming and Antibody Decay","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-11-05","conditions":"Poliomyelitis","enrollment":1645},{"nctId":"NCT04504539","phase":"NA","title":"Use of mOPV1 in Routine Immunization in Pakistan.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-08","conditions":"Oral Polio Vaccine","enrollment":560},{"nctId":"NCT01353703","phase":"PHASE3","title":"Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-16","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":224},{"nctId":"NCT01309646","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-04","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":454},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT03169725","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-05-31","conditions":"Poliomyelitis","enrollment":1417},{"nctId":"NCT01204658","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-27","conditions":"Infections, Streptococcal","enrollment":576},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT03032419","phase":"PHASE3","title":"Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2017-02-06","conditions":"Poliomyelitis","enrollment":1002},{"nctId":"NCT02347423","phase":"PHASE2","title":"3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants","status":"COMPLETED","sponsor":"Statens Serum Institut","startDate":"2015-02","conditions":"Poliomyelitis","enrollment":824},{"nctId":"NCT00290342","phase":"PHASE3","title":"Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-01","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":458},{"nctId":"NCT00586612","phase":"PHASE3","title":"Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":313},{"nctId":"NCT02847026","phase":"PHASE4","title":"Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-09","conditions":"Poliomyelitis","enrollment":1144},{"nctId":"NCT00533507","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-18","conditions":"Infections, Rotavirus","enrollment":230},{"nctId":"NCT00871338","phase":"PHASE2","title":"Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-24","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":284},{"nctId":"NCT02643368","phase":"PHASE4","title":"Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-12","conditions":"Poliomyelitis","enrollment":760},{"nctId":"NCT03128489","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-12-01","conditions":"Diphtheria, Acellular Pertussis, Haemophilus Influenzae Type b","enrollment":""},{"nctId":"NCT03016949","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine","status":"WITHDRAWN","sponsor":"Fidec Corporation","startDate":"2017-07","conditions":"Poliomyelitis","enrollment":""},{"nctId":"NCT00316147","phase":"PHASE3","title":"Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12","conditions":"Diphtheria, Acellular Pertussis, Tetanus","enrollment":224},{"nctId":"NCT02412514","phase":"PHASE4","title":"Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2015-04","conditions":"Poliomyelitis","enrollment":456},{"nctId":"NCT02189811","phase":"PHASE4","title":"Polio End-game Strategies - Poliovirus Type 2 Challenge Study","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2014-09","conditions":"Poliomyelitis","enrollment":900},{"nctId":"NCT01948193","phase":"PHASE3","title":"Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-02","conditions":"Diphtheria, Tetanus, Whooping Cough","enrollment":177},{"nctId":"NCT02291263","phase":"PHASE3","title":"Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2014-10","conditions":"Poliomyelitis","enrollment":738},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT00362336","phase":"PHASE3","title":"Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-08","conditions":"Hepatitis B, Polio, Diphtheria","enrollment":622},{"nctId":"NCT01813604","phase":"PHASE3","title":"Immunogenicity of Inactivated and Live Polio Vaccines","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2012-11","conditions":"Poliomyelitis","enrollment":1206},{"nctId":"NCT00259337","phase":"PHASE3","title":"Immunogenicity and Safety of Pentaxim™ in an Indian Population","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Diphtheria, Tetanus, Polio","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IPV at 6 weeks of age","genericName":"IPV at 6 weeks of age","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"IPV (Inactivated Poliovirus Vaccine) stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by introducing inactivated viral particles. Used for Prevention of poliomyelitis in infants and children, Routine immunization at 6 weeks of age as part of childhood vaccination schedule.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}